source
- BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphomaBeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma. The approval is based on…
- Encoded Therapeutics gene therapy cuts seizures 76% in Dravet syndrome childrenEncoded Therapeutics presented data at the ASGCT26 meeting showing its gene therapy achieved a 76% reduction in seizures among children with Dravet syndrome. The result was observed in three patie…